OUR AIM

Our vision at Accord is to become a top 5 pan-EMENA generics company by 2021 and have developed a specialty products commercialisation capability.

     

Accord UK

Accord Europe

Accord Worldwide

I-4

 

ACCORD UK

Accord Healthcare is one of the fastest growing generic pharmaceutical companies in the UK & Ireland and has an extensive supply chain through its four UK based sites, helping to ensure a consistent supply of life-saving medicines for patients, whilst supporting customers to react quickly to dynamic market conditions.

Acquiring Actavis UK and Ireland in 2017 facilitates Accord’s aim to become the largest supplier of generic medicines in the UK & Ireland and a leading player in the industry at European level.

 

ACCORD EUROPE

Accord is one of the fastest growing generic companies in the world and has one of the most extensive sales, marketing and distribution network in Europe. Headquartered from UK, Accord now supplies products in over 35 European countries. Sales growth in the last 12 months was over 100% bringing revenues of $115 million and significant double digit growth is anticipated in the coming year. Accord has a particular strength in the hospital or institutional setting and last year sales associated with this segment grew 197%.

Accord Europe currently has over 7000 product approvals across 183 INNs and this number is expected to grow significantly over the next few years allowing Accord to compete with some of the biggest portfolios in the industry.

Accord has also invested significantly in an increasing commercial infrastructure across the region and manages its own warehousing, logistics, regulatory, quality, intellectual property and sales and marketing requirements within region. A key value add for Accord Europe is its own warehousing and packaging complex located near Cambridge UK, which facilitates high degree of supply chain flexibility. Accord’s dedicated market sales-forces reach over 97% of the patient population of the EU.

 

ACCORD WORLDWIDE

With an extensive presence in North America, Europe, South America, Australia, New Zealand and South Africa and more recently in the MENA and ASEAN regions, Accord Healthcare has very rapidly become one of the fastest growing generic pharmaceutical companies. With a robust product portfolio in growth segments, such as Oncology, Cardiology, Neurology, Nephrology, Urology, Psychiatry, Diabetology, Pain management and Gastroenterology, Accord’s marketing and distribution network now reaches over 70 countries.

Accord has grown both organically and via acquisition, expanding its product portfolio and operations in various parts of the world. Our North America and European operations were started with a strategic vision to create a global brand in the world’s largest pharmaceutical markets, supported by a commercial infrastructure that enables us to bring our high quality yet affordable products to patients.

Today, the company is marketing over 400 molecules and this number is set to increase significantly over the next few years as a result of a segment leading pipeline and strong in house development capability. Our large and growing portfolio allows us to compete with some of the biggest players in the industry.

Accord is committed to uncompromised quality for its products and services across the globe. Our products are manufactured under the highest international standards and our manufacturing plants are approved by major global regulatory agencies including the USFDA, MHRA, EMA, TGA, MCC, ANVISA. Increasingly Accord is investing in higher barrier to entry developments such as Biosimilar and New Chemical Entities and is set to evolve into a leading global healthcare provider.

INNOVATION

Accord is committed to putting user safety at the heart of our offering. Accord is a dynamic young company unencumbered by past practice and with an appetite for refreshing the way in which safe and efficacious pharmaceuticals are delivered to users, adding innovative features to our concepts and products.

2D Barcode:

Data Matrix is a relatively recent 2- dimensional barcode development. This code has a high data capacity, variable sizing capabilities and ability to withstand harsh environments. It is most commonly used for product identification and lot tracking of pharmaceuticals. Several organisations have recommended the use of Data Matrix due to the advantages it offers:

  • Improved Data Accuracy
  • Faster Data Input and Handling
  • Cost Benefit
  • Flexibility

Different to other companies in the sector, Accord is able to bring closer this advantageous product labelling due to its high technology offering at our manufacturing facilities and product packing site.

PharmaShield® is a system consisting on a superficial plastic sheathing around the vial, going from the reinforced non- PVC base to the vial seal.

Key benefits:

  • Protects from breakage and spillage
  • Protects users from external vial contamination
  • Protects essential product label information
  • The use of non-PVC materials protects the environment
  • Latex free – protects users with sensitivity
  • Reinforced non-PVC base: provides greater stability during manipulation and further reduces risk of breakage if vial dropped

Key benefits of vial seal:

  • No risk of sharp edges that could potentially damage user
  • Minimises potential disruption to crimp as FOC is removed
  • Easy removal of FOC

Other Accord product features

  • Barcode on label: to enhance stock control and reduce potential errors when dispensing the drug
  • Flip-off cap
  • Line code indicates the different strengths available
 

INFRASTRUCTURE

By recognising that our infrastructure must always be appropriate to solving the problem at hand, we have taken a novel approach to our supply of medicines in the fragmented market of Europe. The EU is the world´s biggest trading block encompassing over 550 million people, 27 countries and over 20% of world´s GDP. Whilst each market is very different over the last decade the regulatory procedures required to gain approval to sell pharmaceuticals in the region have been harmonised.

The typical supply lead time from API order to provision of final goods can take over 6 months. Given the many supply shortages that currently exist in the region it is common for demand to fluctuate on a regular basis. It is difficult to adapt to this using a ´make to order´ supply scheme. Instead using a dedicated facility at Haverhill, Cambridgeshire, UK, Accord employs a state of the art ´pack to order´ or postponement strategy.

Put simply we produce large batches of common pharmaceutical product at our EMA and FDA approved facilities and then transfer as nude or undifferentiated products to the packing site. This bulk product is then held ready to pack upon requirement able to go to any of the 27 markets.

By employing this scheme we can shorten lead-times to a matter of weeks. This use of infrastructure is far more suitable to the volatile demand environment of the European trading block than conventional supply chains, all part of our i-4 concept.

 

INTELLIGENCE

Accord’s corporate social responsibility goes beyond our contribution to environment through the application of regulations that favours its sustainability. Our contribution is directed as well to community and specifically to healthcare professionals and patients.

Representative patient support initiatives are book publication of Claudia, One Year of My Life and Kit Appunti di un Viaggio®. Both initiatives have had the cancer patient as central actor bringing benefit to patient as well as family while accompanying the patient through a “Journey” while experiencing secondary effects of chemotherapy and radiotherapy. Kit Appunti di un Viaggio® has been recognised by different oncology associations and even by the Italian Ministry of Health.

 

INVENTION

Rather than simply imitating what has gone before we try to take a more inventive approach to product development. As an example we have reformulated Gemcitabine into a highly concentrated form. Whilst several other companies realised that users would prefer a solution versus the original powder product, they took the approach of making the concentration of the solution match that in the SmPC of the original product.

Instead we stepped back and realised that this approach meant a greater quantity of excipients being given to patients, a greater workload on aseptic pharmacy, greater storage requirements and a greater burden to the environment by having to dispose of more material per patient.

Accord developed the 100 mg/ml Gemcitabine solution. This is unique and offers the following advantages over other solution products:

  • Easier to calculate dosing schedules reducing the chance of dosing errors
  • Less time to withdraw the required dose reducing the burden on aseptic pharmacy
  • Four presentation sizes designed to minimise wastage resulting in financial savings
  • Smaller vials resulting in less use of precious storage space and ultimately reducing the material required to be incinerated; an important environmental improvement
  • Less inactive ingredients being given to patient